Multiple Drug Resistance in Cancer 2 1998
DOI: 10.1007/978-94-017-2374-9_9
|View full text |Cite
|
Sign up to set email alerts
|

Topoisomerase I inhibitors and drug resistance

Abstract: DNA topoisomerase I is a nuclear enzyme which catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. This enzyme represents a novel and distinct molecule target for cancer therapy by antitopoisomerase drugs belonging to the campthotecin series of antineoplastics. As many tumors can acquire resistance to drug treatment and become refractary to the chemotherapy it is very important to investigate the mechanisms involved in such a drug resistance for circumventing … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2001
2001
2004
2004

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 117 publications
0
2
0
Order By: Relevance
“…It is well known that the clinical efficacy of anticancer agents, including some topoisomerase inhibitors, is limited by drug resistance mechanisms (38,39). This resistance can be due to a decrease in the levels and/or activities of topoisomerase, to a decrease of intracellular drug accumulation (MDR phenotype; Ref.…”
Section: Discussionmentioning
confidence: 99%
“…It is well known that the clinical efficacy of anticancer agents, including some topoisomerase inhibitors, is limited by drug resistance mechanisms (38,39). This resistance can be due to a decrease in the levels and/or activities of topoisomerase, to a decrease of intracellular drug accumulation (MDR phenotype; Ref.…”
Section: Discussionmentioning
confidence: 99%
“…Eukaryotic topoisomerase I is a nuclear enzyme capable of introducing transient breaks in one strand of doubled‐strand DNA (Wang 1985). This enzyme is involved in many DNA functions such as replication, transcription and recombination mechanisms (Parchment & Pessina 1998) and has been shown to be the target of antineoplastic drugs of the Camptothecin group (Hsiang et al. 1985), which act by stabilizing the covalent complex between the single‐strand DNA break and the topoisomerase I molecule.…”
Section: Introductionmentioning
confidence: 99%